Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPTLC2 | O15270 | 4/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SPTLC3 | Q9NUV7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979035 | 0.89 | SPTLC2 (0.64) | SPTLC2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6979289 | 0.86 | SPTLC2 (0.71) | SPTLC2PDE4DPDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL6981353 | 0.86 | SPTLC2 (0.56) | SPTLC2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6979836 | 0.83 | SPTLC2 (0.70) | SPTLC2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6981266 | 0.83 | SPTLC2 (0.58) | SPTLC2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6978484 | 0.83 | SPTLC2 (0.66) | SPTLC2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6968663 | 0.83 | SPTLC2 (0.84) | SPTLC2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6977888 | 0.83 | SPTLC2 (0.69) | SPTLC2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6981585 | 0.81 | SPTLC2 (0.75) | SPTLC2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6970294 | 0.80 | SPTLC2 (0.66) | SPTLC2PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1283055-A1 | SOLUBLE BETA AMYLOID PRECURSOR PROTEIN SECRETION PROMOTERS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | APP, BDNF, BACE1 | SPTLC2 3161/4885PDE4D 3075/4885PDE4A 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.